Drugs / Rengalin
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 31 trial | ||||||
| Phase 3 | NCT07171099 | Oct 2025 → Dec 2028 expected | — | Materia Medica Holding | Recruiting | No outcome recorded |
| Phase 41 trial · 1 met primary | ||||||
| Phase 4 | NCT03159091 | Jun 2017 → Apr 2019 | chronic obstructive pulmonary disease | Materia Medica Holding | Completed | Met primary |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Rengalin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03159091 ↗ |
| Route | Oral | “Oral administration.” NCT03159091 ↗ |